Valuation: Beta Bionics, Inc.

Market Cap 790M 683M 642M 583M 1.1B 75.59B 1.12B 7.52B 2.94B 37.85B 2.97B 2.9B 126B P/E 2026 *
-8.21x
P/E 2027 * -8.15x
Enterprise Value 657M 567M 533M 485M 911M 62.8B 926M 6.25B 2.44B 31.45B 2.47B 2.41B 105B EV / Sales 2026 *
4.91x
EV / Sales 2027 * 3.99x
Free-Float
98.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.82%
1 week+10.50%
Current month+36.94%
1 month+3.96%
3 months+85.73%
6 months+26.04%
Current year-42.34%
1 week 16.15
Extreme 16.15
18.32
1 month 12.73
Extreme 12.73
18.32
Current year 8.8
Extreme 8.8
32.58
1 year 8.8
Extreme 8.8
32.71
3 years 8.8
Extreme 8.8
32.71
5 years 8.8
Extreme 8.8
32.71
10 years 8.8
Extreme 8.8
32.71
Manager TitleAgeSince
Chief Executive Officer 50 2022-08-14
Director of Finance/CFO 37 2022-07-31
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 57 2020-01-31
Director/Board Member 50 2022-08-14
Director/Board Member 63 2024-09-30
Date Insider Type Main position Quantity % Market Cap.
6/24/26 Sell

Executive/Senior Manager

-1,258 0.0028%
2/27/26 Sell

Executive/Senior Manager

59,813 0.1359%
2/27/26 Free

Chief Executive Officer

287,944 0.6541%
Change 5-day change 1-year change 3-year change Capi.($)
-2.82%+10.50%+3.11% - 790M
-1.28%-0.96%+20.30%+11.24% 218B
-0.71%-1.13%-4.02%-19.91% 142B
-1.68%+4.14%-17.85%+31.80% 139B
+0.27%+5.11%-49.76%+0.72% 75.11B
-1.04%+2.10%+17.05%+16.26% 52.8B
-0.69%-0.33%-17.34%-15.30% 50.66B
-0.51%+1.75%+24.61%+22.39% 41.95B
-0.32%+1.31%+41.37%+49.96% 40.49B
-0.14%+2.68%+0.40%+4.27% 33.28B
Average -0.89%+2.50%+1.79%+11.27% 79.43B
Weighted average by Cap. -0.91%+1.13%+0.46%+9.18%

Financials

2026 *2027 *
Net sales 134M 116M 109M 98.77M 186M 12.8B 189M 1.27B 498M 6.41B 502M 491M 21.29B 180M 155M 146M 133M 249M 17.19B 254M 1.71B 668M 8.61B 675M 660M 28.61B
Net income -95.11M -82.14M -77.19M -70.2M -132M -9.09B -134M -904M -354M -4.55B -357M -349M -15.13B -96.44M -83.3M -78.27M -71.18M -134M -9.22B -136M -917M -359M -4.62B -362M -354M -15.35B
Net Debt -134M -115M -109M -98.69M -186M -12.79B -189M -1.27B -497M -6.4B -502M -491M -21.28B -73.32M -63.33M -59.51M -54.12M -102M -7.01B -103M -697M -273M -3.51B -275M -269M -11.67B
Logo Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
Employees
422
Date Price Change Volume
26-08-14 US$17.57 -2.82% 935,923
26-08-13 US$18.08 +4.33% 1,503,335
26-08-12 US$17.33 -1.65% 637,904
26-08-11 US$17.62 +7.44% 613,918
26-08-10 US$16.40 +3.14% 1,316,058
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
17.57USD
Average target price
20.31USD
Spread / Average Target
+15.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BBNX Stock